PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer

Kaiser Permanente126 enrolled

Overview

Conduct a prospective study to assess the accuracy of a pancreatic cancer risk prediction model.

The goal of this study is to establish a platform for development and implementation of a data-driven risk model for detection of early stage pancreatic cancer within an integrated health care setting. Patients at increased risk for pancreatic cancer as identified by the risk model will be invited to participate in a prospective study to assess the accuracy of this approach for detection of early stage pancreatic cancer.

Study Type

OBSERVATIONAL

Enrollment

126

Conditions

Pancreatic Cancer Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

Magnetic resonance imaging (MRI)DIAGNOSTIC_TEST

All enrolled participants will undergo magnetic resonance imaging (MRI) at their Baseline and 18-Month follow-up visit

Eligibility

Sex: ALLMin age: 50 YearsMax age: 84 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patient must have 6 months of membership 2. Patient has a measure for weight, Hemoglobin A1C, and Alanine transaminase (ALT) within the past 6 months 3. Patient must have an increased predicted 18-month risk of pancreatic cancer based on the PRO-TECT model 4. Speaks English or Spanish Exclusion Criteria: 1. Previous or current history of pancreatic cancer 2. Metastatic cancer 3. Current active cancer or undergoing chemotherapy for cancer 4. Currently pregnant or breastfeeding 5. Class IV heart failure 6. Cirrhosis with ascites and/or varices 7. Currently in a skilled nursing facility or under hospice care 8. Has metal parts or implanted devices in the body, such as a pacemaker, defibrillator, or shrapnel 9. End stage renal disease 10. Cognitive impairment such that the person is unable to provide informed consent

Locations (1)

Kaiser Permanente Southern California

Pasadena, California, United States

Outcomes

Primary Outcomes

Incidence of pancreatic ductal adenocarcinoma (PDAC) in the high predicted risk group

Enrolled subjects will be followed for 18 months to determine the incidence rate of PDAC

Time frame: 18-Month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.